TSR-033

DRUG2 trials

Sponsors

Tesaro, Inc.

Conditions

Neoplasms

Phase 1

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Active, not recruitingNCT02817633

Tesaro, Inc.Neoplasms

Start: 2016-07-08End: 2027-03-01Updated: 2025-10-28

Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors

CompletedNCT03250832

Tesaro, Inc.Neoplasms

Start: 2017-08-08End: 2023-02-13Updated: 2024-04-11

Related Papers

Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A

Clinical Cancer Research2025-06-247 citations

Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B

Clinical Cancer Research2025-06-243 citations

CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours.

2025-02-271 citations

AMBER part 2F: Cobolimab in combination with dostarlimab in treatment-naïve patients with locally advanced/metastatic and/or unresectable hepatocellular carcinoma (HCC).

Journal of Clinical Oncology2025-01-271 citations

Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study

BMJ Open2024-08-0110 citations

596 AMBER, Part 2B: a phase 1 study of cobolimab plus dostarlimab in patients with advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with anti-PD(L)-1 therapy

Regular and Young Investigator Award Abstracts2023-10-314 citations

Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer.

2023-10-184 citations

Dostarlimab: A Review.

2022-07-2639 citations

Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER).

Journal of Clinical Oncology2022-06-0172 citations

AMBER parts 1c and 1e: A phase 1 study of cobolimab plus dostarlimab in patients (pts) with advanced/metastatic melanoma.

Journal of Clinical Oncology2022-06-0110 citations

Immune Checkpoints are Important Therapeutic Targets in Cancer Immunotherapy

Cancer Science & Research2021-12-30

Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006

European Journal of Cancer2021-09-2724 citations